Mizuho Securities has sustained its positive outlook on Assembly Biosciences (NASDAQ:ASMB) (NASDAQ: ASMB), by reiterating an Outperform rating with a price target of $36.00.
The optimism follows the company's announcement of interim Phase 1a clinical trial data for ABI-5366, a long-acting helicase-primase inhibitor aimed at treating herpes simplex virus (HSV).
The drug, ABI-5366, was reported to be well-tolerated during the trials, with no safety concerns observed. A key point highlighted by Mizuho Securities was the drug's long-acting profile, which appears to be more favorable than initially expected. The possibility of dosing once monthly, rather than weekly, is seen as a significant advantage for patient convenience.
Assembly Biosciences has gained a notable clinical catalyst with the expected interim Phase 1b trial readouts for ABI-5366 in patients with recurrent genital herpes, anticipated in the first half of 2025.
This marks the company's first clinical readout for a patient group outside of chronic hepatitis B virus (cHBV) studies, which typically require longer trial periods. The upcoming readout is expected to draw renewed attention from investors to the company's stock.
In other recent news, Assembly Biosciences announced positive interim results from the Phase 1a study of ABI-5366, a drug candidate for recurrent genital herpes. The study showed a favorable safety profile and tolerability, with the potential for once-weekly or once-monthly oral dosing schedules. The company has started screening participants for the Phase 1b study, which will further assess the drug's antiviral activity.
In addition, the global investment banking firm, Jefferies, upgraded its rating on Assembly Biosciences stock from Hold to Buy, indicating a positive outlook on the company's upcoming clinical data. Jefferies has also increased its price target to $35.00.
Assembly Biosciences is currently developing a long-acting oral treatment for recurrent genital herpes, with Phase IA trial data expected in the third quarter. This data is anticipated to support the potential for once-weekly dosing while maintaining a favorable safety profile.
Finally, Assembly Biosciences is expected to commence its Phase IB trials by the end of the year, with efficacy data anticipated in the first half of 2025.
InvestingPro Insights
As Mizuho Securities maintains a bullish stance on Assembly Biosciences, real-time data from InvestingPro underscores some key financial metrics and expert insights that may be of interest to investors. According to InvestingPro, Assembly Biosciences holds a market capitalization of approximately $103.18 million USD. Despite the company's challenges with profitability, as reflected by a negative P/E ratio of -1.9, analysts are forecasting sales growth in the current year, which may be indicative of potential upside (InvestingPro Tip #1).
Moreover, the stock has experienced a large price uptick over the last six months, with a 25.27% return, aligning with the positive sentiment from the recent clinical trial news (InvestingPro Tip #8). This price performance is noteworthy, especially considering the stock has taken a hit over the last week, with a -10.61% return, potentially offering a more attractive entry point for investors (InvestingPro Tip #2).
While the company does not pay a dividend to shareholders (InvestingPro Tip #9), the anticipation of clinical trial readouts and the potential billion-dollar market for its HSV treatment could be significant drivers of future value. For those interested in a deeper dive, there are additional InvestingPro Tips available, providing a comprehensive analysis that may further inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.